Horm Metab Res 2024; 56(03): 244-254
DOI: 10.1055/a-2184-8945
Original Article: Endocrine Research

LncRNA LINC01339 Hinders the Development of Wilms’ Tumor via MiR-135b-3p/ADH1C Axis

Yang Yu
1   Department of Nephrology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
,
Yanfei Liu
2   Department of Oncology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
› Institutsangaben
Zoom Image

Abstract

Wilms’ tumor is a malignant renal cancer that arises within the pediatric urinary system. This study intended to investigate how a novel long non-coding RNA LINC01339 functions in the pathogenesis of Wilms’ tumor. An elevated miR-135b-3p expression as well as reduced levels of LINC01339 and ADH1C were observed in Wilms’ tumor. LINC01339 mediated ADH1C expression by directly binding to miR-135b-3p. The enforced LINC01339 or ADH1C markedly hindered cell growth and migration in Wilms’ tumor. The LINC01339 overexpression also repressed the growth of Wilms’ tumors in vivo, whereas miR-135b-3p overexpression exerted the opposite effects on Wilms’ tumor cells in vitro. Additionally, upregulating miR-135b-3p reversed LINC01339’s effects on the cellular processes of Wilms’ tumor cells, whereas ADH1C overexpression offset the cancer-promoting influence of miR-135b-3p upregulation on Wilms’ tumor progression. Therefore, LINC01339 prevents Wilms’ tumor progression by modulating the miR-135b-3p/ADH1C axis. Our findings substantiate that the LINC01339/miR-135 b-3p/ADH1C regulatory axis has potential to be a target for the treatment of Wilms’ tumor.

Supplementary Material



Publikationsverlauf

Eingereicht: 01. Juni 2023

Angenommen nach Revision: 26. September 2023

Artikel online veröffentlicht:
27. Oktober 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany